Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy

Pulmonary arterial hypertension (PAH) is a progressive disease that causes severe disability and has no cure. Over the past 20 years, a variety of treatment options have evolved for the management of PAH. With an expanded therapeutic armamentarium come more complex decisions regarding treatment opti...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, Mitchell S, Staib, Robin L, Wicks, Laura M, Feldman, Jeremy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108715/
https://www.ncbi.nlm.nih.gov/pubmed/21701627
http://dx.doi.org/10.2147/DHPS.S6215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108715/
https://www.ncbi.nlm.nih.gov/pubmed/21701627
http://dx.doi.org/10.2147/DHPS.S6215

Ejemplares similares